IRJIF:5.012

North Asian International Research Journal of Pharmaceutical & Medical Sciences

ISSN: 2456-8287 Vol. 8, Issue-2 February-2024

Index Copernicus Value: 61.14 Fulfill MCI Criteria Indian Citation Index

NAIRJC A Peer Reviewed Refereed International Journal

DOI: 10.5859/nairjpms.2024.10.02.2

DON OF HOPE: STARVING PANCREATIC CANCER BY GLUTAMINE ANTAGONISM

***DR NISAR HUSSAIN MALIK**

Medical Officer J&K Govt Health Services (*PHC Gulzarpora** *)*

ABSTRACT

Pancreatic cancer remains one of the most aggressive and challenging malignancies, with limited treatment options and a high mortality rate. Despite advances in understanding its molecular underpinnings, effective therapeutic strategies are still elusive. This research paper explores a novel approach to combat pancreatic cancer by targeting glutamine metabolism, specifically through the use of the potent glutamine antagonist, 6-diazo-5-oxo-L-norleucine (DON). The paper delves into the molecular mechanisms underlying pancreatic cancer progression, the critical role of glutamine in sustaining cancer cell survival, and the potential of DON to disrupt these processes, offering a beacon of hope in the battle against this devastating disease.

KEYWORDS: ***Pancreatic cancer, Glutamine metabolism, 6-diazo-5-oxo-L-norleucine (DON), Glutaminase, Molecular mechanisms, Therapeutic targets, Tumor microenvironment, Preclinical studies, Clinical trials, Combination therapy***

1. INTRODUCTION:

Pancreatic cancer is a lethal malignancy with a dismal prognosis, characterized by late-stage diagnosis, rapid progression, and resistance to conventional therapies. The quest for innovative and effective treatment modalities is imperative to improve patient outcomes. Glutamine, a non-essential amino acid, has emerged as a key player in the metabolic rewiring of cancer cells, including pancreatic cancer. This paper explores the role of glutamine in pancreatic cancer and investigates the therapeutic potential of 6-diazo-5-oxo-L-norleucine (DON) as a glutamine antagonist.

2. GLUTAMINE METABOLISM IN PANCREATIC CANCER:

Pancreatic cancer cells exhibit heightened metabolic demands to sustain their rapid proliferation and survival. Glutamine, a versatile amino acid, plays a pivotal role in providing energy, maintaining redox balance, and serving as a precursor for nucleotide and amino acid synthesis. Pancreatic cancer cells often exhibit an increased reliance on glutamine metabolism, presenting a potential vulnerability for therapeutic intervention.

3. THE DON COMPOUND:

6-diazo-5-oxo-L-norleucine (DON) is a potent glutamine antagonist that has shown promise in preclinical studies against various cancer types. DON inhibits the enzyme glutaminase, which catalyzes the conversion of glutamine to glutamate, thereby disrupting the glutamine-dependent metabolic pathways crucial for cancer cell survival. This section details the pharmacological properties of DON and its mechanism of action.

4. MOLECULAR MECHANISMS OF DON IN PANCREATIC CANCER:

The paper explores how DON interferes with key molecular pathways involved in pancreatic cancer progression. This includes the disruption of energy metabolism, induction of oxidative stress, and inhibition of nucleotide synthesis. Additionally, the impact of DON on the tumor microenvironment and its potential to sensitize pancreatic cancer cells to existing therapies will be discussed.

5. PRECLINICAL AND CLINICAL EVIDENCE:

A comprehensive review of preclinical studies involving DON in pancreatic cancer models provides insights into its efficacy and safety profile. Furthermore, ongoing or completed clinical trials investigating the use of DON in pancreatic cancer patients will be discussed, shedding light on the translational potential of this approach.

6. CHALLENGES AND FUTURE DIRECTIONS:

While the therapeutic potential of DON is promising, challenges such as drug delivery, potential side effects, and resistance mechanisms need to be addressed. The paper will also outline potential combination strategies and future avenues of research to enhance the effectiveness of glutamine antagonism in the treatment of pancreatic cancer.

7. CONCLUSION:

In conclusion, targeting glutamine metabolism through the use of DON presents a compelling avenue for the development of innovative therapies against pancreatic cancer. This research paper provides a comprehensive overview of the molecular mechanisms involved, preclinical and clinical evidence, and outlines future directions for

refining and advancing this approach. The DON of Hope may represent a novel and much-needed strategy in the ongoing battle against pancreatic cancer, offering renewed optimism for improved patient outcomes.

REFERENCES:

[1]. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101-105.

[2]. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48):18782-18787.

[3]. Delage B, Luong P, Maharaj L, et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis. 2012;3:e342.

[4]. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678-3684.

[5]. Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res. 2009;15(22):7853-7861.

[6]. Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9(8):454-467.

[7]. Roczniak-Ferguson A, Petit CS, Froehlich F, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42.

[8]. Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res. 1964;24:389-399.